Fig 1.
(A) A representative result of the MBP-QP method to detect C797S T2389A mutation by using control plasmid. (B) A representative result of the MBP-QP method to detect C797S G2390C mutation by using control plasmid.
Table 1.
T790M detection with ctDNA and re-biopsy before and after afatinib treatment, and response to afatinib.
Fig 2.
Change of detection of T790M and C797S just before afatinib treatment and at PD under afatinib.
*Neither ctDNA nor re-biopsy samples were obtained at PD under afatinib.
Table 2.
C797S, V600E, and MET amplification detection with ctDNA and re-biopsy at PD to afatinib.
Fig 3.
Serial analysis of T790M and C797S mutations in patient 5.
Black arrows show mutant peaks by the MBP-QP method. The negative sign (-) indicates undetectable by droplet digital PCR (ddPCR), and the numbers are allele frequencies determined by ddPCR.
Table 3.
T790M and C797S detection at PD to afatinib and effect of osimertinib.